NR3C2 and heart failure: From 2016 until recently, the main drugs to treat patients with symptomatic heart failure with reduced ejection fraction were beta blockers, angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB), mineralocorticoid receptor (MR), and angiotensin receptor neprilysin inhibitor (ARNI) [11].